Author

D. A. Brooks

University of South Australia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

A. J. Hoy· 1 shared Cara M. MartiniD· 1 shared D. C. Miller· 1 shared E. S. Evergren· 1 shared Eva F. HayballiD· 1 shared Fiona O’ConnelliD· 1 shared I. R. Johnson· 1 shared J. Dehairs· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. J. Hoy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Design, Synthesis, and Efficacy of Novel Trojan Horse Compounds Targeting Metabolic Vulnerabilities in Prostate Cancer

Laura Bogue Edgerton, Eva F. Hayball, Fiona O’Connell, M. P. Ward, Sharon A. O’Toole, Cara M. Martin, Stavros Selemidis, R. D. Brooks, Prerna Tewari, D. A. Brooks, John J. O’Leary

This study designs and tests Trojan Horse compounds targeting metabolic vulnerabilities in prostate cancer, showing promising cytotoxicity and selectivity in PCa cell lines.

bioRxiv · Aug 29, 2024 · PreprintCancer Biology

Cis-vaccenic acid is a key product of stearoyl-CoA desaturase 1 and a critical oncogenic factor in prostate cancer

J. S. Scott, R. S. Young, L.-E. Quek, D. C. Miller, E. S. Evergren, J. Dehairs, I. R. Johnson, D. A. Brooks, M. Loda, A. J. Hoy, S. J. Blanksby, J. V. Swinnen, Z. D. Nassar, L. M. Butler

This study identifies cis-vaccenic acid as a critical oncogenic factor in prostate cancer, showing it rescues cell viability loss from SCD1 inhibition and promotes growth.

bioRxiv · Mar 28, 2024 · PreprintCell Biology